AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00846040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional MRI (fMRI) will be used to measure the effects of diet and weight loss on regional brain activity
Study NCT00846040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Study NCT00846040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET
Description: Positron emission tomography (PET) will be used to assess whether To assess whether brain activity and reward pathways are altered
Study NCT02904122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: teleconsultation
Description: Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
Study NCT03433391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgery Only
Description: Single level partial discectomy as per standard of care procedures.
Study NCT03200418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hydrocolloid adhesive
Description: This patch is made of standard hydrocolloid adhesive
Study NCT03200418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-4
Description: This patch is made of new adhesive
Study NCT03200418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-15
Description: This patch is made of new adhesive
Study NCT03200418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P-16
Description: This patch is made of new adhesive
Study NCT03624959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: ozanimod
Study NCT03624959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Description: Gemfibrozil
Study NCT03624959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole
Study NCT01044316 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) vaccine
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
Study NCT04202029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thoracic impedance monitoring
Description: Thoracic impedance measurement identifies the respiratory frequence using the changes of impedance during inspiration and expiration via an ECG.
Study NCT04202029 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: pulseoxymetry
Description: Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
Study NCT04202029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulseoxymetry
Description: Pulseoxymetry is meassuring the heart rate and the oxygen saturation in the arterial blood
Study NCT04202029 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: non-invasive blood preassure monitoring
Description: Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
Study NCT03958591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII and thereafter combination therapy, followed up with wearable devices
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up the participants.
Study NCT03958591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSII and thereafter combination therapy, followed up in traditional ways
Description: Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used for follow up.
Study NCT03958591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditionally upgrading therapy, followed up in traditional ways
Description: The participants will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used for follow up.
Study NCT03596073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Calcipotriene Ointment
Description: Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
Study NCT03596073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vaseline
Description: Placebo
Study NCT03971604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: treated with Vitamin A
Study NCT03971604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: treated with Vitamin E
Study NCT03674099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Tablets 400 mg
Study NCT03674099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 1 g tablets or infusion
Study NCT05661305 — intervention group
Intervention type: OTHER
Intervention: Whole Genome Sequencing to compare healthy volunteers genome with that of cardiomyopathies patients.
Description: Egyptian patients and their family members diagnosed with different types hereditary cardiomyopathies.Healthy Egyptian individuals to provide the first of its kind resource on human genetic variation in Egyptians, which is essential for understanding the significance of detected variations in patients with inherited cardiovascular disease and their families.
Study NCT02446873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg supplementation
Description: A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
Study NCT04970160 — intervention group
Intervention type: PROCEDURE
Intervention: TSARP
Description: We make four different surgical operations for female patients with rectovestibular fistula
Study NCT04970160 — intervention group
Intervention type: PROCEDURE
Intervention: PSARP
Description: Posterior sagittal anorectoplasty
Study NCT04202029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive blood preassure monitoring
Description: Non-invasive blood preassure is a method using a blood preassure cuff to identify the blood preassure.
Study NCT04991155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: BIA 5-1058 (tablets 100 mg) was administered orally with 240 mL (Part 1) or 270 mL (Part 2 and Part 3) of water, in one period in the morning under fasting conditions (after at least a 10-hour overnight fast), in one period in the morning after a moderate meal, and in the other period at lunch after a moderate meal.
Study NCT03116607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient education/ recommendations to the health team
Description: The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
Study NCT02607891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT02532075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Warm Up
Description: Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
Study NCT02607891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT00003644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Study NCT00003644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT04970160 — intervention group
Intervention type: PROCEDURE
Intervention: Classic ASARP
Description: Anterior Sagittal anorectoplasty
Study NCT04970160 — intervention group
Intervention type: PROCEDURE
Intervention: Modified ASARP
Description: External anal sphincter preservation
Study NCT02532075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory Warm Up
Description: Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
Study NCT02532075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Warm Up
Description: Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
Study NCT03624959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin
Study NCT01855828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
Study NCT01855828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total).
Study NCT01855828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
Study NCT01855828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Study NCT01855828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
Study NCT01855828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
Study NCT01331629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART-THERAPIE
Description: 8 sessions of art therapy during radiotherapy
Study NCT04087434 — intervention group
Intervention type: DEVICE
Intervention: Brain Gauge Prospective and Healthy Control
Description: The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
Study NCT02242981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally
Study NCT01151605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin infusion
Description: insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
Study NCT01151605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin infusion
Description: insulin to be infused at 3.5 units/hour along with Dextrose 12.5% at a rate to achieve blood glucose levels between 80-120mg/dl
Study NCT00003644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT00003644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT02318511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knee injection
Description: Injection into knee for the treatment of Osteoarthritis
Study NCT02318511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee injection
Description: Injection into knee for the treatment of Osteoarthritis
Study NCT02318511 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Knee injection
Description: Injection into knee for the treatment of Osteoarthritis
Study NCT00664599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotoxic Combination
Description: Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
Study NCT00799409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/ CONCERTA (methylphenidate HCl)
Description: Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
Study NCT02532075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Trial
Description: Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
Study NCT02318511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ReNu amniotic allograft
Study NCT02318511 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline
Study NCT00799409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CONCERTA (methylphenidate HCl) / Placebo
Description: Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
Study NCT02318511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study NCT03683849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: One hour of training, twice a week, for six months.
Study NCT00487747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks
Study NCT03683849 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: One hour of training, twice a week, for six months.
Study NCT03543059 — intervention group
Intervention type: DRUG
Intervention: GnRH analogue
Description: gonadotrophin releasing hormone analogue
Study NCT00825344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg subcutaenous preoperatively
Study NCT00825344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given subcutaneously preoperatively
Study NCT00895596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380
Description: Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
Study NCT01235767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
Study NCT02709889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Study NCT02709889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be provided through a participant's local prescription by Investigator or other provider (i.e., dexamethasone will not be provided by the Sponsor).
Study NCT03637959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Vibrations with Ultrasound Shear Wave Imaging
Description: Multiple miniature mechanical vibrators will be placed on the body surface of rib cage of the subject or introduced through an audio loudspeaker in contact with the subject's upper torso or through miniature vibrator attached to the ultrasound probe. Repeated ultrasound stiffness measurements will be made at different locations within the liver parenchyma while the mini vibrators introduce shear wave in the liver, similar to an MRE examination.
Study NCT03700931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating recall condition
Description: Recall of eating episodes would increase subsequent intake of fruit or vegetable items
Study NCT03700931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-eating recall condition
Description: Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
Study NCT03236935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-NMMA
Description: pan-nitric oxide synthase inhibitor
Study NCT03236935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PD-1 inhibitor
Study NCT04184921 — intervention group
Intervention type: DRUG
Intervention: Aspirin 100mg
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
Study NCT00807716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking skill group
Description: 12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
Study NCT00807716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual physiotherapy care
Description: physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
Study NCT04613492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9253
Description: Participants will receive either Single dose MEDI9253 or Multiple Dose MEDI9253; sequentially or concurrent with Durvalumab
Study NCT04613492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab treatment will be started sequentially or concurrently with MEDI9253
Study NCT02558439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975
Study NCT02558439 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03138590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS
Description: Transcranial Direct Current Stimulation targeting the trigeminal nerve
Study NCT03138590 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS
Description: Transcranial Direct Current Stimulation targeting the trigeminal nerve
Study NCT01657812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery.
Study NCT01151605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose infusion
Description: Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
Study NCT01151605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose infusion
Description: Dextrose 12.5% will be infused at a rate to maintain blood glucose level 80-120mg/dl
Study NCT01151605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Infusion
Description: Saline will be infused at 100ml/hr
Study NCT01151605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Infusion
Description: Saline will be infused at 100ml/hr
Study NCT02226198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Description: Active drug will be taken taken orally, QD, either in the morning or in the evening
Study NCT02226198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be taken taken orally, QD, either in the morning or in the evening
Study NCT04126720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: topical corticosteroids and vitamin E suplements
Study NCT03845907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gen 1B
Description: Diagnostic Ultrasound and Optoacoustic Imaging
Study NCT01657812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery.
Study NCT04126720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid and placebo capsules